Literature DB >> 17982390

Persistent hyperestrogenism after precocious puberty in young females with McCune-Albright syndrome.

Roberto Lala1, Maria Andreo, Angela Pucci, Patrizia Matarazzo.   

Abstract

In this review we report the literature about ovarian function of young women with McCune-Albright Syndrome and describe our personal experience in the follow-up of a small cohort.Collectively, the existing data demonstrate that ovarian hyperfunction with ovarian cysts and hyperestrogenism persists in those women who had precocious puberty. The recording of menstrual cycles and the analysis of gonadotropin and estrogen secretion indicate that, when hypothalamic-pituitary pubertal activation begins, alternating episodes of gonadotropin control and ovarian autonomy can be seen. The persistence of estrogen hypersecretion causes menstrual disturbances and hypofertility. The long term consequences of this condition are hypothesized to be an increased risk of ductal breast cancer, which seems to be higher when growth hormone hypersecretion is also present. Therefore, young MAS women should receive counseling regarding fertility and ongoing surveillance for the development of estrogen related diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982390

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  3 in total

Review 1.  Cutaneous mosaicism: Special considerations for women.

Authors:  Katharine T Ellis; Diana Ovejero; Keith A Choate
Journal:  Int J Womens Dermatol       Date:  2021-10-27

2.  Treatment of Pathological Bone Fractures in a Patient with McCune-Albright Syndrome.

Authors:  Jana Kollerova; Tomas Koller; Zuzana Zelinkova; Ludmila Kostalova; Juraj Payer
Journal:  Case Rep Endocrinol       Date:  2013-11-28

Review 3.  Auxological and Endocrinological Features in Children With McCune Albright Syndrome: A Review.

Authors:  Maria Tufano; Daniele Ciofi; Antonella Amendolea; Stefano Stagi
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-04       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.